Therapeutic composition comprising a botulinum neurotoxin

Details Therapeutic composition comprising a botulinum neurotoxin Therapeutic composition comprising a botulinum neurotoxin

2011-06-21

2011-06-21

Ford, Vanessa L. (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Bacterium or component thereof or substance produced by said...

C424S184100, C424S234100, C424S236100, C530S300000, C530S324000

Reexamination Certificate

active

07964199

ABSTRACT:
A pharmaceutical preparation comprising one of the botulinum neurotoxins fromClostridium botulinumof types A, B, C, D, E, F or G or a mixture of two or more of these neurotoxins, wherein the neurotoxin or the mixture of neurotoxins is free of the complexing proteins which naturally form the botulinum neurotoxin complexes together with the neurotoxins.

REFERENCES:
patent: 5512547 (1996-04-01), Johnson et al.
patent: 5846929 (1998-12-01), Johnson et al.
patent: 6358917 (2002-03-01), Carruthers et al.
patent: 6787517 (2004-09-01), Gil et al.
patent: 466407 (2002-01-01), None
patent: WO 94/26308 (1994-11-01), None
patent: WO 94/28923 (1994-12-01), None
patent: WO 95/17904 (1995-07-01), None
patent: WO 95/30431 (1995-11-01), None
patent: WO 97/35604 (1997-10-01), None
patent: WO 0074703 (2000-12-01), None
Goeschel et al, Experimental Neurology, 147, 1997, pp. 96-102.
Keen et al, Plastic and Reconstructive Surgery, Jul. 1994, 94, No. 1, pp. 94-99.
Shelley et al (J Am Acad Dermatol. 1998, 28:227-9).
Benedetto, International Journal of Dermatology, 1999, 28, 641-655.
Goeschel et al, (Experimental Neurology, 147, 1997, pp. 96-102).
Borodic et al (Ophthalmic Plastic and Reconstructive Surgery, vol. 9, No. 3, p. 182-190).
Keen et al (Plastic and Reconstructive Surgery, Jul. 1994, 94, No. 1, pp. 94-99).
Jankovic et al (The New England Journal of Medicine, Apr. 25, 1991).
Carruthers et al, Cosmetic Uses of Botulinum Toxin A Exotoxin. In:Klein AW, ed. Tissue Augmentation in Clinical Practice: Procedures and Techniques. New York: Marcel Dekker, 1998:207-236).
Heckman et al (Arch Dermatol, vol. 134, Oct. 1998).
Kessler (J Neurol (1999) 246:265-274).
Goschel et al, (Experimental Neurology, 147, 1997, pp. 96-102).
Green et al (Movement Disorders, vol. 8, No. 4, 1993, p. 479-483).
Carruthers et al (Basic and Clinical Dermatology, Marcel Dekker, Inc, New York, 1998, Chapter 11, pp. 207-236).
Shelley et al (Journal of the American Academy of Dermatology, Feb. 1998, pp. 227-229).
Webster's II New Riverside University Dictionary, The Riverside Publishing Company, 1984.
Borodic et al (Ophthalmic Plastic and Reconstructive Surgery, 1993, vol. 9, No. 3, p. 182-190).
Hatheway CL and Dang C, Immunogenicity of the immunotoxins ofClostridium botulinum. In: Jankovic J and Hallett M, eds.Therapy with botulinum toxin. New York: Marcel Dekker, 1994, pp. 93-97.
Greene P, Fahn S and Diamond B. 1994. Development of Resistance toBotulinumToxin Type A in Patients with Torticollis. Movement Disorders 9:213-217.
Jankovic J and Schwartz K. 1995. Response and immunoresistance tobotulinumtoxin injections. Neurobiology 45:1743-1746.
Borodic, Johnson E Goodnough M and Schantz E. 1996.Botulinumtoxin therapy, immunologic resistance, and problems with available materials. Neurology 46:26-29.
Dertzbaugh MT and West MW. 1996. Mapping of protective and cross-reactive domains of the type a neurotoxin ofClostridium botulinum. Vaccine 14:1538-1544.
Doellgast GJ, Brown JE, Koufman JA and Hatheway C. 1997. Sensitive Assay for Measurement of Antibodies toClostridium botulinumNeurotoxins A, B, and E: Use of Hapten-Labeled Antibody Elution To Isolate Specific Complexes. J. Clinical Microbiol. 35:578-583.
Dressler D. 1997.Botulinumtoxin therapy failure: causes, evaluation procedures and management strategies. European J. Neurology 4 (suppl 2):S67-S70.
Brin MF. 1997.BotulinumToxin: Chemistry, Pharmacolocy, Toxicity, and Immunology. Muscle & Nerve Supplement 6:S146-S168.
Kessler KR, Skutta M and Benecke R. 1999. Long-term treatment of cervical dystonia withbotulinumtoxin A: efficacy, safety, and antibody frequency. J. Neurol. 246:265-274.
Aoki, KR. 1999. Preclinical update on BOTOX® (botulinumtoxin type A)-purified neurotoxin complex relative to otherbotulinumneurotoxin preparations. European Journal of Neurology 6 (suppl. 4):S3-S10.
Brashear A. 2001. TheBotulinumToxins in the Treatment of Cervical Dystonia. Seminars in Neurology 21:85-90.
Aoki KR and Guyer B. 2001Botulinumtoxin type A and otherbotulinumtoxin serotypes: a comparative review of biochemical and pharmacological actions. European Journal of Neurology 8 (suppl. 5):21-29.
Jankovic J.BotulinumToxin: Clinical Implications of Antigenicity and Immunoresistance. In: Brin MF, Jankovic J and Hallett M eds.Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins, 2002, pp. 409-415.
Aoki KR. Immunologic and Other Properties of TherapeuticBotulinumToxin Serotypes. . In: Brin MF, Jankovic J and Hallett M eds.Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins, 2002, pp. 103-113.
Aoki KR. Physiology and Pharmacology of TherapeuticBotulinumNeurotoxins. In: Kreyden OP, Böni R and Burg G eds.Hyperhidrosis and Botulinum Toxin in Dermatology. Curr Probl Dermatol, Basel: Karger, 2002, vol. 30, pp. 107-116.
Aoki KR 2002.Botulinumneurotoxin serotypes A and B preparations have different safety margins in preclinical models of muscle weakening efficacy and systemic safety. Toxicon 40:923-928.
Eleopra R, Tungnoli V Quatrale R Rossetto O, Montecucco C and De Grandis D.BotulinumNeurotoxin Serotypes C and E: Clinical Trials. In: Brin MF, Jankovic J and Hallett M eds.Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia: Lippincott Williams & Wilkins 2002, pp. 441-450.
Münchau A, Palmer JK, Dressler K, O'Sullivan JD Tsang KL, Jahanshahi M, Quinn NP, Lees AJ, Bhatia KP. 2001. Prospective study of selective peripheral denervation forbotulinum-toxin resistant patients with cervical dystonia. Brain 124:769-83.
Wohlfahrt, et al. Proceedings of Biomedical Aspects of Clostridial neurotoxins. Intl Conference Oxford-Jul. 7-11, 1996, p. 165.
Balash, et al. European Journal of Neurology, 2004, 11:361-370.
Comella, et al. Muscle and Nerve, May 2004, vol. 29, pp. 628-644.
BOTOX® Cosmetic, Product Insert, Jan. 2005.
Dressler, D. , 2005, Latest results on non-response to conventionalbotulinumtoxin treatment. Interview with PD Dr. D. Dressler, University of Rostock.
Lew, et al. Neurology, 1997, 49:701-707.
Troung, et al. Movement Disorders, 1997, 12:772-775.
Truong, et al. Movement Disorders, 1995, 10:394.
Australian Opposition 774590—BENEKE Declaration—2006.
Australian Opposition—Benecke Declaration—ANNEX—2006.
Australian Opposition 774590—FRAZER Declaration—2005.
Australian Opposition 774590—FRAZER Declaration—ANNEX—2005.
Australian Opposition 774590—NATTRASS Declaration—2006.
Australian Opposition 774590—NATTRASS Declaration—ANNEX—2006.
Australian Opposition 774590—O'Sullivan Declaration—2005.
Australian Opposition 774590—PATON Declaration—2006.
Australian Opposition 774590—PATON Declaration—ANNEX—2006.
Australian Opposition 774590—Tanks Declaration—2005.
Australian Opposition 774590—Statement of Grounds and Particulars—Jun. 12, 2007.
Dressler, et al. Archives of Pharmacology, 365: R18, 2002.
European Patent 1185291—Grounds of Opposition—2004.
European Patent 1185291—Result of Oral Proceeding—Feb. 16, 2006.
European Patent 1185291—Notice of Appeal—May 24, 2006.
European Patent 1185291—Opponent Submission—Dec. 16, 2005.
European Patent 1185291—Opponent Submission—Jan. 24, 2006.
European Patent 1185291—Patentee Submission—Aug. 3, 2007.
European Patent 1185291—Opposition Decision—Apr. 6, 2006.
European Patent 1185291—Withdrawal of Opposition—Sep. 6, 2007.
European Patent 1185291—Maintenance of Patent—Jun. 10, 2010.
Jankovic, et al. Movement Disorders, 20, P105, 2005.
Wohlfahrt, et al. In: Trunter HS, ed. Proceedings of Biomedical Aspects of Clostridial Neurotoxin Intl. Conf. Oxford, Center for Applied Microbiology and Research:165, 1996.
Chen, et al. Neurology 51:1494-1496, 1998.
Hanna, et al. J. Neurol. Neurosurg. Psychiatry 66:612-613,1999.
Sankhla, et al. Movement Disorders

Affiliated with

Also associated with

Rating

Therapeutic composition comprising a botulinum neurotoxin does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic composition comprising a botulinum neurotoxin, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic composition comprising a botulinum neurotoxin will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2681048